country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-149360

Copy Link Print Information

P-gb-IN-1

P-gb-IN-1 (compound Ⅲ-8), a 2,5-disubstituted furan derivative, is a highly effective, broadspectrum P-glycoprotein (P-gp) inhibitor. P-gb-IN-1 displayed the reversal activity by inhibiting P-gp efflux. P-gb-IN-1 has a potent affinity to P-gp by forming H-bond interactions with residues Asn 721 and Met 986. P-gb-IN-1 possesses broad-spectrum reversal activity and low toxicity in MCF-7/ADR cells.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

CAS No.: 2632874-49-6
Formule: C₃₀H₂₈N₂O₆
Masse moléculaire:512.55

Stockage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (265 KB)

P-gb-IN-1 Chemical Structure

CAS No.: 2632874-49-6

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- Cellular Effect
Chemical Information
Pureté et documentation
Références
Calculators
Help & FAQs
Classifications
Bioz

Activité biologique

Description

Cellular Effect

Cell Line	Type	Value	Description	References
NCI/ADR-RES	IC₅₀	0.09 μM Compound: Cpd III-8	Cytotoxicity against human MCF7ADR cells assessed as doxorubicin IC50 at 5 uM incubated for 48 hrs by CCK8 assay Cytotoxicity against human MCF7ADR cells assessed as doxorubicin IC50 at 5 uM incubated for 48 hrs by CCK8 assay	[PMID: 37229830]
NCI/ADR-RES	IC₅₀	0.09 μM Compound: Cpd III-8	Sensitization of doxorubicin-induced antitumor activity against human MCF7ADR cells assessed as doxorubicin IC50 at 5 uM incubated for 48 hrs by CCK8 assay Sensitization of doxorubicin-induced antitumor activity against human MCF7ADR cells assessed as doxorubicin IC50 at 5 uM incubated for 48 hrs by CCK8 assay	[PMID: 37229830]
NCI/ADR-RES	IC₅₀	0.36 μM Compound: Cpd III-8	Sensitization of daunorubicin-induced antitumor activity against human MCF7ADR cells assessed as daunorubicin IC50 at 5 uM incubated for 48 hrs by CCK8 assay Sensitization of daunorubicin-induced antitumor activity against human MCF7ADR cells assessed as daunorubicin IC50 at 5 uM incubated for 48 hrs by CCK8 assay	[PMID: 37229830]
NCI/ADR-RES	IC₅₀	0.37 μM Compound: Cpd III-8	Sensitization of paclitaxel-induced antitumor activity against human MCF7ADR cells assessed as paclitaxel IC50 at 5 uM incubated for 48 hrs by CCK8 assay Sensitization of paclitaxel-induced antitumor activity against human MCF7ADR cells assessed as paclitaxel IC50 at 5 uM incubated for 48 hrs by CCK8 assay	[PMID: 37229830]
NCI/ADR-RES	IC₅₀	0.53 μM Compound: Cpd III-8	Sensitization of vincristine-induced antitumor activity against human MCF7ADR cells assessed as vincristine IC50 at 5 uM incubated for 48 hrs by CCK8 assay Sensitization of vincristine-induced antitumor activity against human MCF7ADR cells assessed as vincristine IC50 at 5 uM incubated for 48 hrs by CCK8 assay	[PMID: 37229830]
NCI/ADR-RES	IC₅₀	15.5 μM Compound: Cpd III-8	Cytotoxicity against human MCF7ADR cells assessed as doxorubicin IC50 at 0.1 uM incubated for 48 hrs by CCK8 assay Cytotoxicity against human MCF7ADR cells assessed as doxorubicin IC50 at 0.1 uM incubated for 48 hrs by CCK8 assay	[PMID: 37229830]
NCI/ADR-RES	IC₅₀	5.78 μM Compound: Cpd III-8	Cytotoxicity against human MCF7ADR cells assessed as doxorubicin IC50 at 0.5 uM incubated for 48 hrs by CCK8 assay Cytotoxicity against human MCF7ADR cells assessed as doxorubicin IC50 at 0.5 uM incubated for 48 hrs by CCK8 assay	[PMID: 37229830]

Chemical Information

CAS No. 2632874-49-6
Masse moléculaire 512.55
Formule C₃₀H₂₈N₂O₆
SMILES

O=C(NC1=CC=C(C2=CC=C(C(N3CCC(C=C(OC)C(OC)=C4)=C4C3)=O)O2)C=C1)C5=CC=C(OC)C=C5
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

Please store the product under the recommended conditions in the Certificate of Analysis.

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (265 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Zhikun Yang, et al. Discovery of 2,5-disubstituted furan derivatives featuring a benzamide motif for overcoming P-glycoprotein mediated multidrug resistance in MCF-7/ADR cell. Eur J Med Chem. 2023 Sep 5;257:115462. [Content Brief]

Calculators

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

MOQ

Minimum order quantity

100 mg

Obtenir un devis En stock

Other size

Obtenir un devis